<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.27159.032</object-id><label>Table 1.</label><caption><title>Clinical characteristics of patients at HSPC biopsy and initiation of abiraterone treatment.</title><p>HSPC: hormone sensitive biopsy, CRPC: castration-resistant prostate cancer, ECOG PS: Eastern Cooperative Oncology Group performance status, IQR: interquartile range, SD: standard deviation, NA: not available, PSA: prostate specific antigen, n: number, pts: patients.</p><p><supplementary-material id="table1sdata1"><object-id pub-id-type="doi">10.7554/eLife.27159.033</object-id><label>Table 1&#8212;source data 1.</label><caption><title>Association of nuclear Bag-1 or AR expression with clinical benefits from abiraterone therapy.</title><p>HSPC: hormone sensitive prostate cancer, CRPC: castration-resistant prostate cancer, PSA: prostate specific antigen, HR: hazard ratio, 95% CI: 95% confidence intervals. <sup>a</sup> Univariate cox survival model.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-27159-table1-data1-v2.docx"/></supplementary-material></p><p><supplementary-material id="table1sdata2"><object-id pub-id-type="doi">10.7554/eLife.27159.034</object-id><label>Table 1&#8212;source data 2.</label><caption><title>Clinical characteristics of patients at time of castration-resistant prostate cancer biopsy.</title><p>CRPC: castration-resistant prostate cancer, ECOG PS: Eastern Cooperative Oncology Group performance status, IQR: interquartile range, SD: standard deviation, PSA: prostate specific antigen, n: number, pts: patients. <sup>a</sup>t-test from linear regression model of Nuclear Bag-1 H-score at the time of CRPC biopsy <sup>b</sup>Wald test from linear regression model of Nuclear Bag-1 H-score at the time of CRPC biopsy</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-27159-table1-data2-v2.docx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" valign="top"/><th valign="top">Overall <break/>38 pts</th><th valign="top">Bag-1 negative <break/>9 pts</th><th valign="top">Bag-1 positive <break/>29pts</th><th valign="top">p-value</th></tr></thead><tbody><tr><td rowspan="16" valign="top">At diagnostic <break/>(archival) <break/>HSPC biopsy</td><td valign="top">Biopsy Gleason score, n (%)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8804;6</td><td valign="top">2 (5)</td><td valign="top">0 (0)</td><td valign="top">2 (7)</td><td valign="top">0.40<sup>&#8224;</sup></td></tr><tr><td valign="top">7</td><td valign="top">7 (18)</td><td valign="top">4 (44)</td><td valign="top">3 (10)</td><td valign="top"/></tr><tr><td valign="top">8&#8211;10</td><td valign="top">27 (71)</td><td valign="top">5 (56)</td><td valign="top">22 (76)</td><td valign="top"/></tr><tr><td valign="top">NA</td><td valign="top">2 (5)</td><td valign="top">0 (0)</td><td valign="top">2 (7)</td><td valign="top"/></tr><tr><td valign="top">Metastatic at diagnosis, n (%)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">No</td><td valign="top">17 (45)</td><td valign="top">2 (22)</td><td valign="top">15 (52)</td><td valign="top">0.25<sup>&#167;</sup></td></tr><tr><td valign="top">Yes</td><td valign="top">14 (37)</td><td valign="top">4 (44)</td><td valign="top">10 (34)</td><td valign="top"/></tr><tr><td valign="top">NA</td><td valign="top">7 (18)</td><td valign="top">3 (33)</td><td valign="top">4 (14)</td><td valign="top"/></tr><tr><td valign="top">Primary therapy, n (%)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Prostatectomy</td><td valign="top">4 (11)</td><td valign="top">0 (0)</td><td valign="top">4 (14)</td><td valign="top">0.65<sup>&#167;</sup></td></tr><tr><td valign="top">Radiotherapy</td><td valign="top">13 (34)</td><td valign="top">3 (33)</td><td valign="top">10 (34)</td><td valign="top"/></tr><tr><td valign="top">Systemic therapy</td><td valign="top">21 (55)</td><td valign="top">6 (67)</td><td valign="top">15 (52)</td><td valign="top"/></tr><tr><td valign="top">PSA at diagnosis, &#956;g/L</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Median</td><td valign="top">46.0</td><td valign="top">61.0</td><td valign="top">29.0</td><td valign="top">0.30*</td></tr><tr><td valign="top">IQR</td><td valign="top">13.1&#8211;105.9</td><td valign="top">28.8&#8211;150.0</td><td valign="top">10.0&#8211;96.6</td><td valign="top"/></tr><tr><td rowspan="25">At initiation of <break/>abiraterone treatment</td><td valign="top">Age, yr</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Median</td><td valign="top">69.2</td><td valign="top">69.5</td><td valign="top">69.0</td><td valign="top">0.59*</td></tr><tr><td valign="top">IQR</td><td valign="top">65.5&#8211;73.3</td><td valign="top">61.6&#8211;74.1</td><td valign="top">66.1&#8211;73.3</td><td valign="top"/></tr><tr><td valign="top">Sites of metastasis, n (%)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Node only</td><td valign="top">4 (11)</td><td valign="top">0 (0)</td><td valign="top">4 (14)</td><td valign="top">0.57<sup>&#167;</sup></td></tr><tr><td valign="top">Bone only</td><td valign="top">28 (74)</td><td valign="top">7 (78)</td><td valign="top">21 (72)</td><td valign="top"/></tr><tr><td valign="top">Visceral (with/without bone)</td><td valign="top">6 (16)</td><td valign="top">2 (22)</td><td valign="top">4 (14)</td><td valign="top"/></tr><tr><td valign="top">ECOG PS, n (%)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">0</td><td valign="top">12 (32)</td><td valign="top">6 (67)</td><td valign="top">6 (21)</td><td valign="top">0.05<sup>&#167;</sup></td></tr><tr><td valign="top">1</td><td valign="top">24 (63)</td><td valign="top">3 (33)</td><td valign="top">21 (72)</td><td valign="top"/></tr><tr><td valign="top">2</td><td valign="top">2 (5)</td><td valign="top">0 (0)</td><td valign="top">2 (7)</td><td valign="top"/></tr><tr><td valign="top">PSA, &#956;g/L</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Median</td><td valign="top">185.5</td><td valign="top">222.0</td><td valign="top">147.0</td><td valign="top">0.77*</td></tr><tr><td valign="top">IQR</td><td valign="top">83.8&#8211;445.8</td><td valign="top">51.2&#8211;781.5</td><td valign="top">88.0&#8211;363.0</td><td valign="top"/></tr><tr><td valign="top">Hemoglobin, g/L</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Mean</td><td valign="top">118.1</td><td valign="top">124.4</td><td valign="top">116.2</td><td valign="top">0.18<sup>&#8225;</sup></td></tr><tr><td valign="top">SD</td><td valign="top">16.0</td><td valign="top">16.3</td><td valign="top">15.7</td><td valign="top"/></tr><tr><td valign="top">Alkaline phosphatase, U/L</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Median</td><td valign="top">131.0</td><td valign="top">133.0</td><td valign="top">129.0</td><td valign="top">0.85*</td></tr><tr><td valign="top">IQR</td><td valign="top">69.0&#8211;230.5</td><td valign="top">64.5&#8211;250.5</td><td valign="top">70.0&#8211;231.0</td><td valign="top"/></tr><tr><td valign="top">Lactate dehydrogenase, U/L</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Median</td><td valign="top">178.0</td><td valign="top">161.0</td><td valign="top">192.0</td><td valign="top">0.08*</td></tr><tr><td valign="top">IQR</td><td valign="top">155.5&#8211;247.0</td><td valign="top">149.5&#8211;190.0</td><td valign="top">160.0&#8211;287.0</td><td valign="top"/></tr><tr><td valign="top">NA</td><td valign="top">2</td><td valign="top">0</td><td valign="top">2</td><td valign="top"/></tr><tr><td valign="top">Albumin, g/L</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td rowspan="10"/><td valign="top">Mean</td><td valign="top">35.8</td><td valign="top">37.8</td><td valign="top">35.2</td><td valign="top">0.17<sup>&#8225;</sup></td></tr><tr><td valign="top">SD</td><td valign="top">4.8</td><td valign="top">2.4</td><td valign="top">5.2</td><td valign="top"/></tr><tr><td valign="top">Previous treatments for CRPC, n (%)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Docetaxel</td><td valign="top">27 (71)</td><td valign="top">5 (55)</td><td valign="top">22 (76)</td><td valign="top">0.40<sup>&#167;</sup></td></tr><tr><td valign="top">Enzalutamide</td><td valign="top">2 (5)</td><td valign="top">0 (0)</td><td valign="top">2 (7)</td><td valign="top">1.00<sup>&#167;</sup></td></tr><tr><td valign="top">Cabazitaxel</td><td valign="top">5 (13)</td><td valign="top">0 (0)</td><td valign="top">5 (17)</td><td valign="top">0.31<sup>&#167;</sup></td></tr><tr><td valign="top">Subsequent treatments for CRPC, n (%)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Docetaxel</td><td valign="top">8 (21)</td><td valign="top">4 (44)</td><td valign="top">4 (14)</td><td valign="top">0.07<sup>&#167;</sup></td></tr><tr><td valign="top">Enzalutamide</td><td valign="top">7 (18)</td><td valign="top">1 (11)</td><td valign="top">6 (21)</td><td valign="top">1.00<sup>&#167;</sup></td></tr><tr><td valign="top">Cabazitaxel</td><td valign="top">15 (39)</td><td valign="top">5 (55)</td><td valign="top">10 (34)</td><td valign="top">0.44<sup>&#167;</sup></td></tr></tbody></table><table-wrap-foot><fn><p>*Mann-Whitney test</p><p><sup>&#8224;</sup>Chi-square test for trend</p></fn><fn><p><sup>&#8225;</sup>Unpaired t test</p><p><sup>&#167;</sup>Fisher&#8217;s exact test</p></fn></table-wrap-foot></table-wrap>